253 related articles for article (PubMed ID: 29995803)
1. Treatment outcomes and HIV drug resistance of patients switching to second-line regimens after long-term first-line antiretroviral therapy: An observational cohort study.
Cao P; Su B; Wu J; Wang Z; Yan J; Song C; Ruan Y; Xing H; Shao Y; Liao L
Medicine (Baltimore); 2018 Jul; 97(28):e11463. PubMed ID: 29995803
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
Wang J; Wang Z; Liu J; Yue Y; Yang S; Huang H; He C; Liao L; Xing H; Ruan Y; Shao Y
Sci Rep; 2015 Oct; 5():14823. PubMed ID: 26445885
[TBL] [Abstract][Full Text] [Related]
3. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
[TBL] [Abstract][Full Text] [Related]
5. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
6. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
Jiamsakul A; Sungkanuparph S; Law M; Kantor R; Praparattanapan J; Li PC; Phanuphak P; Merati T; Ratanasuwan W; Lee CK; Ditangco R; Mustafa M; Singtoroj T; Kiertiburanakul S;
J Int AIDS Soc; 2014; 17(1):19053. PubMed ID: 25141905
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
[TBL] [Abstract][Full Text] [Related]
8. Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study.
Modica S; Redi D; Gagliardini R; Giombini E; Bezenchek A; Di Carlo D; Maggiolo F; Lombardi F; Borghetti A; Farinacci D; Callegaro A; Gismondo MR; Colafigli M; Sterrantino G; Costantini A; Ferrara SM; Rusconi S; Zazzi M; Rossetti B; De Luca A; Gianotti N
J Antimicrob Chemother; 2020 Jan; 75(1):194-199. PubMed ID: 31605107
[TBL] [Abstract][Full Text] [Related]
9. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic.
Charpentier C; Gody JC; Mbitikon O; Moussa S; Matta M; Péré H; Fournier J; Longo Jde D; Bélec L
AIDS Res Hum Retroviruses; 2012 Jan; 28(1):87-94. PubMed ID: 21599597
[TBL] [Abstract][Full Text] [Related]
10. [Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].
Brunner J; Seybold U; Gunsenheimer-Bartmeyer B; Hamouda O; Bogner JR;
Dtsch Med Wochenschr; 2010 Jun; 135(23):1166-70. PubMed ID: 20514595
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients on second line antiretroviral therapy under programmatic condition in India.
Chakravarty J; Sundar S; Chourasia A; Singh PN; Kurle S; Tripathy SP; Chaturbhuj DN; Rai M; Agarwal AK; Mishra RN; Paranjape RS
BMC Infect Dis; 2015 Nov; 15():517. PubMed ID: 26572102
[TBL] [Abstract][Full Text] [Related]
12. High turnaround times and low viral resuppression rates after reinforced adherence counselling following a confirmed virological failure diagnostic algorithm in HIV-infected patients on first-line antiretroviral therapy from Tanzania.
Kroidl A; Burger T; Urio A; Mugeniwalwo R; Mgaya J; Mlagalila F; Hoelscher M; Däumer M; Salehe O; Sangare A; Lennemann T; Maganga L
Trop Med Int Health; 2020 May; 25(5):579-589. PubMed ID: 31984634
[TBL] [Abstract][Full Text] [Related]
13. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
14. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
16. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.
Sigaloff KC; Hamers RL; Wallis CL; Kityo C; Siwale M; Ive P; Botes ME; Mandaliya K; Wellington M; Osibogun A; Stevens WS; van Vugt M; de Wit TF;
J Acquir Immune Defic Syndr; 2011 Sep; 58(1):23-31. PubMed ID: 21694603
[TBL] [Abstract][Full Text] [Related]
17. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
[TBL] [Abstract][Full Text] [Related]
18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
19. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
[TBL] [Abstract][Full Text] [Related]
20. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]